The best minds, working in tandem, conduct the best science.
Collaborating
We seek to collaborate with exceptional partners to advance novel treatments through agile science, delivering better medicines to the patients that need them. We want to have the best people working on the best science, and that means being—and finding—excellent partners.
If you are interested in partnering with us, please fill out our contact form.
Our Current Partners
Evommune and Accutar have formed a partnership focused on the discovery of novel small molecule drug candidates that target the root cause of chronic inflammatory diseases. Accutar employs a sophisticated hybrid approach that integrates computational drug design with wet lab validation, overcoming many limitations of traditional drug discovery methods. By combining Evommune’s deep biological expertise with Accutar’s medicinal chemistry engine, we aim to develop the next generation of therapies for chronic inflammatory diseases.
Evommune has entered into a strategic collaboration with Maruho Co., Ltd., to exclusively develop and commercialize EVO756 (MRGPRX2 small molecule antagonist) in Japan, Greater China, and other key Asian markets. Maruho is a globally respected organization that has developed and commercialized pharmaceuticals in Japan for more than 100 years. We believe this collaboration marks the beginning of a long-term, multifaceted relationship between Evommune and Maruho, with the potential to accelerate development and expand patient access to EVO756 across Asia.